HanAll Biopharma appoints Christopher W. Slavinsky as chief business development and legal officer
HanAll Biopharma said it appointed Christopher W. Slavinsky as its chief business development and legal officer, a move aimed at accelerating the company's global business expansion.
Slavinsky brings over 25 years of experience in legal and business development within the biotech and large pharmaceutical sectors, managing companies with annual revenues ranging from $50 million to $50 billion.
Slavinsky graduated with a degree in biochemistry from the State University of New York at Stony Brook, a master's in biochemistry and molecular biology from Thomas Jefferson University, and a Juris Doctor degree from the University of Washington School of Law.
His comprehensive expertise spans the entire drug development process, and he has successfully led transactions exceeding $20 billion, including M&As and licensing of drug candidates.
Prior to joining HanAll Biopharma, Slavinsky served as the chief business development and legal officer at Coherus BioSciences, where he spearheaded the $65 million acquisition of Surface Oncology, an immunotherapy developer.
He also played a role in commercializing the Humira biosimilar Yusimly at Coherus BioSciences and establishing a partnership agreement with Cost Plus Drugs, a company specializing in discounted pharmaceuticals.
Aside from his roles at Coherus BioSciences, Slavinsky held executive positions at several global companies, including Pfizer, Takeda Pharmaceuticals, Pharmacosmos Therapeutics, and Prometheus Biosciences.
"With Slavinsky's extensive experience at major global companies, we expect he will significantly contribute to our pipeline commercialization and the introduction of new pipelines, greatly aiding our global business expansion," HanAll Biopharma President and CEO Jeong Seung-won said.
Slavinsky shared his enthusiasm about joining HanAll Biopharma, stating, "I am excited to join HanAll Biopharma, a company with specialized expertise in drug development, and I look forward to collaborating with various academic and industry partners to provide effective treatments to patients."